

## Today's issue of PD

*Pharmacy Daily* today features two pages of news, plus full pages from:

- Crampeze
- MediChoice OSTEO-CAPS

## Ease cramps

**CRAMPEZE** contains magnesium and *Viburnum opulus* (cramp bark) to help relieve night cramps, mild muscle twitches and spasms.

Available in two different strengths - more on **page three**.

## Osteo control

**NEW** MediChoice OSTEO-CAPS from Nova Pharmaceuticals provides up to eight hours of relief from osteoarthritis pain.

The pharmacist-only medicine contains 665mg of paracetamol and comes in a pack of 96 - more on **page four**.

## Kids' homeopathy safety recall

**KEY** Sun Laboratories is recalling one batch of Key Sun Kids Travel Sickness Homeopathic Product, due to the risk of a small metal wire being present in the lozenge.

A lollypop from batch number 7266 was found to contain a piece of wire, most likely originating from manufacturing equipment.

The wire could result in a child cutting their mouth or damaging their digestive tract.

Products from the affected batch should be returned to place of purchase - more **HERE**.

## Aussie men's health clinic goes global

**PIONEERING** pharmacist-led men's health initiative, Men's Health Downunder (MHDU), has expanded internationally and is now starting to provide the same expert services in a number of locations across the Republic of Ireland.

Founded in 2013 by Canberra pharmacist Brad Butt (**pictured**) to break down the stigma surrounding male urological health conditions, MHDU aims to ensure men can access the care, rehabilitation and advice they need to ensure the best outcomes post-treatment.

MHDU is now the largest men's health pharmacist-led clinic in Australia, providing support and tailored solutions for a wide range of male health issues.

With referrals from GPs, urologists and sexual health clinics, MHDU operates across major cities and regional centres nationwide, offering accessible, specialist care for men at every stage of their health journey.

Butt also co-authored a new handbook to help pharmacists

**4 ways to help build strong bones**

Available from Symbion, Sigma, API & CH2

Always read the label and follow the directions for use.

support patients managing erectile dysfunction for the International Pharmaceutical Federation (FIP) this year (**PD** 30 May).

The clinic caught the eye of Daragh Connolly, Chair of the FIP Board of Pharmaceutical Practice, when he visited Australia for the FIP World Congress last year.

"I was blown away by the service, because of its simplicity, accessibility and relevance," Connolly said.

"I knew if it worked in Brisbane it could work in my community pharmacy in Dungarvan.

"As soon as I met Brad and learned of his work establishing MHDU, I knew this was a service we were missing in Ireland, but I also knew instinctively that these people are professionals driven by a passion to improve men's health and lives.

"We're proud to strengthen what community pharmacy can offer, and this marks the beginning of an exciting new chapter for patients."

Butt is delighted that MHDU is expanding into Ireland, saying it is



an incredible opportunity to reach even more men who often put their health on the backburner.

"If we can give them a trusted place to start the conversation and point them toward the right support, that alone can make a life-changing difference," Butt explained.

"Men everywhere face the same barriers, whether its cost-of-living pressures, embarrassment, or the belief they'll 'come good' on their own, so taking MHDU's specialised model of care abroad is a vital step.

"By connecting men with practical advice, targeted support and the right clinicians, we can help them take control of their health much sooner." **KB**

## New treatments, and first of kind self-test for gonorrhoea

**THE** US Food and Drug Administration (FDA) has approved GSK's Blujepa (gepolidacin) and Innoviva's Nuzolve (zoflodacin) for the treatment of uncomplicated urogenital gonorrhoea in adults and adolescents, the first drugs from new antibiotic classes to be approved for the disease in over three decades.

As gonorrhoea becomes increasingly challenging to treat due the spread of antimicrobial resistance to many antibiotics previously used as first-line therapies, the approvals have

been welcomed by health experts worldwide.

GSK has submitted Blujepa for Therapeutic Goods Administration (TGA) approval.

The news comes as a self-test kit for chlamydia and gonorrhoea developed by Sydney-based Touch Biotechnology hits pharmacy shelves in Australia, having been approved by the TGA last month.

The first of its kind in Australia, the highly accurate test detects chlamydia and gonorrhoea with one swab sample, collected in privacy at home, producing a positive or negative result for

both infections in 15 minutes.

"It marks significant progress in improving the options for female sexual health in Australia, hopefully reducing the number of infections that go undiagnosed and enabling more people to receive appropriate and timely treatment for infection that prevents further health complications," said CEO of Touch Biotechnology, Matt Salihi.

"While this self-test can aid early detection, comprehensive STI screening and follow-up care are best managed in consultation with a healthcare provider," he added.

One Done with



Athlete's Foot Treatment in a Single Step



GET FEET OFF YOUR MIND

For more information, call 02 8878 9777 to talk to your Pharmabroker representative.

Always read the label and follow the directions for use.